<PAGE>
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------
SCHEDULE 14D-1
TENDER OFFER STATEMENT PURSUANT TO SECTION 14(d)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 4)
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 4)
----------------
INCONTROL, INC.
(NAME OF SUBJECT COMPANY)
PEGASUS ACQUISITIONS CORP.
AN INDIRECT WHOLLY-OWNED SUBSIDIARY OF
GUIDANT CORPORATION
(BIDDERS)
----------------
COMMON STOCK, PAR VALUE $0.01 PER SHARE
(TITLE OF CLASS OF SECURITIES)
45336L103
(CUSIP NUMBER OF CLASS OF SECURITIES)
----------------
J.B. KING, ESQ.
GUIDANT CORPORATION
111 MONUMENT CIRCLE
INDIANAPOLIS, IN 46204-5129
(317) 971-2000
(NAMES, ADDRESS AND TELEPHONE NUMBER OF PERSON AUTHORIZED TO RECEIVE NOTICES
AND COMMUNICATIONS ON BEHALF OF BIDDER)
----------------
COPIES OF COMMUNICATIONS TO:
BERNARD E. KURY, ESQ.
JONATHAN L. FREEDMAN, ESQ.
DEWEY BALLANTINE LLP
1301 AVENUE OF THE AMERICAS
NEW YORK, NY 10019
(212) 259-8000
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE>
This Amendment No. 4 amends and supplements the Tender Offer Statement on
Schedule 14D-1/Schedule 13D, initially filed August 17, 1998, as amended (the
"Schedule 14D-1"), of Guidant Corporation, an Indiana corporation, and its
wholly-owned subsidiaries, Cardiac Pacemakers, Inc., a Minnesota corporation,
and Pegasus Acquisitions Corp., a Delaware corporation ("Purchaser"), relating
to Purchaser's tender offer for all of the outstanding stock of InControl,
Inc., a Delaware corporation, upon the terms and subject to the conditions set
forth in the Offer to Purchase, dated August 17, 1998 (the "Offer to
Purchase"). Unless otherwise defined herein, all capitalized terms used herein
shall have the respective meanings given such terms in the Offer to Purchase
or the Schedule 14D-1.
ITEM 2(G). IDENTITY AND BACKGROUND.
The response to Item 2(g) is hereby amended and supplemented as follows:
Ruedi E. Wager, Ph.D., a director of Parent, is a citizen of both France
and Switzerland.
ITEM 10. ADDITIONAL INFORMATION.
The response to Item 10 is hereby amended and supplemented as follows:
On September 2, 1998, Parent and the Company issued the joint press
release attached hereto as Exhibit (a)(9). The information set forth in the
press release is incorporated herein by reference.
ITEM 11. MATERIAL TO BE FILED AS EXHIBITS.
<TABLE>
<CAPTION>
EXHIBIT
NUMBER DESCRIPTION OF DOCUMENT
------- ----------------------------------------------------------------------------
<S> <C>
(a)(9) Form of press release issued by Parent and the Company on September 2, 1998.
</TABLE>
<PAGE>
SIGNATURE
After due inquiry and to the best of my knowledge and belief, each of the
undersigned certifies that the information set forth in this Statement is
true, complete and correct.
Dated: September 4, 1998
Pegasus Acquisitions Corp.
/s/ A. Jay Graf
By: _________________________________
A. Jay Graf
President
Cardiac Pacemakers, Inc.
/s/ A. Jay Graf
By: _________________________________
A. Jay Graf
President and Chief Executive
Officer
Guidant Corporation
/s/ A. Jay Graf
By: _________________________________
A. Jay Graf
Vice President
<PAGE>
For Immediate Release
Date: September 2, 1998
Guidant Contacts:
Todd McKinney, Investor Relations, 317/971-2094
Carol A. Lindahl, Media Relations, 651/582-4461
Rob Allen, Media Relations, 317/971-2031
InControl Contacts:
Phil M. Okeson, 425/861-9800. Ext. 157
Sean M. Cleary, 425/861-9800. Ext. 660
GUIDANT ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO
WAITING PERIOD FOR INCONTROL TENDER OFFER
INDIANAPOLIS, Ind. and REDMOND, Wash.--SEPTEMBER 2, 1998--Guidant
Corporation (NYSE:GDT) and InControl, Inc. (NASDAQ:INCL) today announced that
the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of
1976 has expired with respect to Guidant's pending cash tender offer for all
of the outstanding shares of InControl common stock at a price of $6.00 per
share. The tender offer is scheduled to expire at midnight, New York City
time, on Monday, September 14, 1998.
InControl, Inc., based in Redmond, Washington, is a pioneer in the design,
development and manufacture of implantable atrial defibrillators and related
products.
A global leader in the medical device industry, Guidant Corporation, based
in Indianapolis, Indiana, provides innovative, minimally invasive and cost-
effective products and services for the treatment of cardiovascular and
vascular disease.
For more information on Guidant, visit Guidant's Web site at
http://www.guidant.com.
For more information on InControl, visit InControl's Web site at
http://www.incontrol.com.
